Cerulean Pharma Inc. (NASDAQ:DARE) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Tuesday, August 1st.
Shares of Cerulean Pharma (NASDAQ DARE) traded down 1.43% during midday trading on Tuesday, hitting $2.76. The stock had a trading volume of 41,267 shares. The firm has a 50-day moving average price of $4.87 and a 200-day moving average price of $7.60. The firm’s market cap is $8.01 million. Cerulean Pharma has a 1-year low of $2.63 and a 1-year high of $35.80.
Cerulean Pharma Company Profile
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.